Nature Cancer

Nature Cancer is a journal dedicated to publishing the latest advances across all areas of cancer research.

[Nature Cancer @NatureCancer]

📢Our September Issue is out!

Read about generative AI for digital pathology, cancer immunometabolism, GITR antibody optimization, l-glutamine combination therapy, and more

🔗https://t.co/mvd61FMvNV

[Nature Cancer @NatureCancer]

@Guiping_W @CRUK_CI Hi Guiping, this is Julieta Alfonso from Nature Cancer, I was trying to reach out, you can contact me at [email protected], thanks!

[Nature Cancer @NatureCancer]

Attending #ESMO26? Our Senior Editor, @Vin_Giacco, will be there and looks forward to connecting with the oncology community. Get in touch to discuss your latest research and publishing opportunities at Nature Cancer.

[Vincenzo Giacco, PhD @Vin_Giacco]

Looking forward to attending the #ESMO26 Annual Meeting in Madrid! I'll be there representing @NatureCancer and meeting the oncology community.

Happy to discuss your latest research, publishing opportunities, or ideas for the journal, please reach out.

See you in Madrid 🇪🇸

[Nature Cancer @NatureCancer]

🧬New in Nature Cancer:
The phase 2 PEGASUS trial explores a ctDNA-guided strategy to de-escalate or escalate adjuvant therapy in patients with high-risk stage II and stage III colon cancer, moving us closer to more personalised treatment decisions.

https://t.co/KYQjEuGoBW

[Nature Cancer @NatureCancer]

📢Read our Series on Next-generation cancer therapeutics featuring commissioned Reviews and a selection of articles published in Nature Cancer!

https://t.co/OlYSbcbZtx

[Nature Cancer @NatureCancer]

🚨New in Nature Cancer

Dr Gong and colleagues report findings from the phase 1 study evaluating L-glutamine + gemcitabine/nab-paclitaxel in untreated advanced PDAC. ORR 44%, including 12.5% CR, with median OS of 22 months. #PancreaticCancer @jgong15

https://t.co/wmLOzWIMSW

[Nature Cancer @NatureCancer]

Now Online!
The neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance.

https://t.co/Lu523MQGEi

[Nature Cancer @NatureCancer]

Our August issue is live!🏖️

Featuring copper dependency in AML, iron-mediated ferroptosis, GPNMB-directed CAR-T cell therapy, IDH1-mutant vaccine in phase 1 trial, and more

🔗https://t.co/W0zfTQZYs5

[Nature Cancer @NatureCancer]

The full agenda for Reframing Precision Medicine is now live.

We created this event with the goal of moving medicine beyond theory to show how multi-omics, AI, and big data can make truly personalised care the norm.

Join us in London: https://t.co/MMqlRNEAFD

[Nature Cancer @NatureCancer]

💫Online today
The Review on intratumor heterogeneity by @Jonathancmwan, @NickyMcGranahan and @CharlesSwanton

🔗https://t.co/i5ryGR2lej

Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: https://t.co/kJQO5ZYuOC

[Nature Conferences @NatureConf]

Join @NancyFGoodman, @Gilles_Vassal and 15 other global experts at our event with @StJudeResearch, looking to address urgent challenges and opportunities in childhood cancer care. Secure a seat and submit an abstract by Aug 6. https://t.co/kEYdKqOPcO

[Nature Cancer @NatureCancer]

☀️Check out our July issue !

✅Tertiary lymphoid structures
✅DNA vaccine for GBM
✅CAR T cell therapy in lung metastases
✅adjuvant chemotherapy in nasopharyngeal carcinoma
✅neutrophil-driven contact-dependent immune suppression
✅GABA in GBM
https://t.co/eUbkfI58Sh

[Nature Cancer @NatureCancer]

🌟Online today

A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages
https://t.co/JG9TwwTWLC

[Tullia Bruno, PhD @BcellBruno]

Great week for the Bruno lab for publications. Check out our new commentary on #TLS in @NatureCancer
@PittTweet @UPMCHillmanCC
https://t.co/5AKwTSnMlR

[Nature Cancer @NatureCancer]

In first-in-human phase 1 NOA16 trial, Platten and colleagues report the long-term clinical and immunological follow-up outcomes of a vaccine targeting mutant IDH1 in persons with astrocytoma. @Platten_lab
https://t.co/7Lw6fjO8cV

[Nature Cancer @NatureCancer]

🌻Check out our June issue !

✅Metastatic dissemination in CRC
✅Immunotherapy in GBM
✅BH3 mimetics sensitization in AML
✅ctDNA and PSA to monitor prostate cancer
✅Methylation-based CNS tumor classification
and more

https://t.co/4jxi0Zwu3k

[Nature Cancer @NatureCancer]

Zemp at al. found GPNMB as a targetable antigen for MiT/TFE-family fusion-driven soft-part sarcoma and translocation RCC and tested GPNMB-directed CAR T cell therapy in preclinical models and in first-in-human trial.

Read the N&Vs: https://t.co/VgtaRmGzbs
https://t.co/54sB3Qf9pB

[Nature Cancer @NatureCancer]

🚨Check out our last release

Bayik and colleagues show that inhibition of GABBR signaling extends survival in female glioblastoma models, highlighting the potential for sex-specific cancer treatments and the unique immune landscape shaped by GABA

https://t.co/T1NWv1g9ji

[Nature Cancer @NatureCancer]

⭐️Online now

Iron level and ferroptosis impair antitumor efficacy of CAR-T cells.

by Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang & colleagues
https://t.co/wyhVPkUHKg

[Nature Cancer @NatureCancer]

📢Online now!

@MoritzGerstung, Felix Sahm & co developed an AI algorithm that leverages H&E slides to classify central nervous system tumors into methylation-based subtypes reducing turnaround time to 12 min in prospective evaluation.

https://t.co/DGhFA6Rt6H